Overview

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects

Status:
Recruiting
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
This study is to compare PK, PD, safety, tolerability, and immunogenicity profiles of SB16, EU sourced Prolia, and US sourced Prolia in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Samsung Bioepis Co., Ltd.
Treatments:
Denosumab